文献速递焦虑、强迫与应激相关障碍

布瑞哌唑与舍曲林联合治疗创伤后应激障碍:一项3期随机临床试验

Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder: A Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2025-01-01

这项在美国86个临床试验点开展的平行设计、双盲、随机、活性对照试验纳入416例成人PTSD门诊患者,比较布瑞哌唑2至3 mg/日联合舍曲林150 mg/日与舍曲林150 mg/日联合安慰剂治疗11周的疗效与安全性;第10周联合治疗组CAPS-5总分改善显著优于对照组(LS均值差-5.59,95%CI -8.79至-2.38,P<.001),大多数参与者耐受良好。

要点

  • 第10周布瑞哌唑+舍曲林组CAPS-5总分LS均值变化-19.2,舍曲林+安慰剂组-13.6,LS均值差-5.59(95%CI -8.79至-2.38,P<.001)。
  • 所有关键次要及其他疗效终点也均达到。
  • 因不良事件停药率:布瑞哌唑+舍曲林组3.9%(8/205),舍曲林+安慰剂组10.2%(20/196)。

核心结论

  • 布瑞哌唑+舍曲林联合治疗较舍曲林+安慰剂统计学显著改善PTSD症状,提示其作为PTSD新型有效治疗方法的潜力。
  • 布瑞哌唑+舍曲林为大多数参与者所耐受,安全性特征与布瑞哌唑在已批准适应症中的安全性特征一致。

研究设计与样本

  • 平行设计、双盲、随机、活性对照临床试验,2019年10月至2023年8月在美国86个临床试验点开展。
  • 研究包括1周安慰剂导入期,随后为11周双盲、随机、活性对照、平行组治疗期(含21天随访)。
  • 入组对象为成人PTSD门诊患者(志愿者样本),共评估1327例资格,878例筛选失败后416例被随机分组(平均[SD]年龄37.4[11.9]岁;女性310例[74.5%])。
  • 干预为口服布瑞哌唑2至3 mg/日(灵活剂量)+舍曲林150 mg/日,或舍曲林150 mg/日+安慰剂,按1:1比例分组,治疗11周。

主要发现

  • 完成率:布瑞哌唑+舍曲林组137/214例(64.0%),舍曲林+安慰剂组113/202例(55.9%)。
  • 第10周CAPS-5总分:布瑞哌唑+舍曲林组随机化时均值(SD)38.4(7.2),LS均值(SE)变化-19.2(1.2),n=148;舍曲林+安慰剂组随机化时38.7(7.8),变化-13.6(1.2),n=134;LS均值差-5.59(95%CI -8.79至-2.38;P<.001)。
  • 所有关键次要及其他疗效终点也均达到。
  • 发生率≥5%的治疗中出现的不良事件(布瑞哌唑+舍曲林组与舍曲林+安慰剂组对应发生率):恶心25/205(12.2%)与23/196(11.7%),疲乏14/205(6.8%)与8/196(4.1%),体重增加12/205(5.9%)与3/196(1.5%),嗜睡11/205(5.4%)与5/196(2.6%)。
  • 因不良事件停药率:布瑞哌唑+舍曲林组8/205例(3.9%),舍曲林+安慰剂组20/196例(10.2%)。

关键数值与推荐

  • 主要终点为从随机化(第1周)至第10周CAPS-5总分(测量20项PTSD症状严重程度)的变化,比较布瑞哌唑+舍曲林与舍曲林+安慰剂。
  • 安全性评估包括不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: New pharmacotherapy options are needed for posttraumatic stress disorder (PTSD). OBJECTIVE: To investigate the efficacy, safety, and tolerability of brexpiprazole and sertraline combination treatment (brexpiprazole + sertraline) compared with sertraline + placebo for PTSD. DESIGN, SETTING, AND PARTICIPANTS: This was a parallel-design, double-blind, randomized clinical trial conducted from October 2019 to August 2023. The study had a 1-week, placebo run-in period followed by an 11-week, double-blind, randomized, active-controlled, parallel-arm period (with 21-day follow-up) and took place at 86 clinical trial sites in the US. Adult outpatients with PTSD were enrolled (volunteer sample). INTERVENTIONS: Oral brexpiprazole 2 to 3 mg per day (flexible dose) + sertraline 150 mg per day or sertraline 150 mg per day + placebo (1:1 ratio) for 11 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score (which measures the severity of 20 PTSD symptoms) from randomization (week 1) to week 10 for brexpiprazole + sertraline vs sertraline + placebo. Safety assessments included adverse events. RESULTS: A total of 1327 individuals were assessed for eligibility. After 878 screen failures, 416 participants (mean [SD] age, 37.4 [11.9] years; 310 female [74.5%]) were randomized. Completion rates were 137 of 214 participants (64.0%) for brexpiprazole + sertraline and 113 of 202 participants (55.9%) for sertraline + placebo. At week 10, brexpiprazole + sertraline demonstrated statistically significant greater improvement in CAPS-5 total score (mean [SD] at randomization, 38.4 [7.2]; LS mean [SE] change, -19.2 [1.2]; n = 148) than sertraline + placebo (randomization, 38.7 [7.8]; change, -13.6 [1.2]; n = 134), with LS mean difference, -5.59 (95% CI, -8.79 to -2.38; P < .001). All key secondary and other efficacy end points were also met. Treatment-emergent adverse events with incidence of 5% or greater for brexpiprazole + sertraline (and corresponding incidences for sertraline + placebo) were nausea (25 of 205 [12.2%] and 23 of 196 [11.7%]), fatigue (14 of 205 [6.8%] and 8 of 196 [4.1%]), weight increase (12 of 205 [5.9%] and 3 of 196 [1.5%]), and somnolence (11 of 205 [5.4%] and 5 of 196 [2.6%]). Discontinuation rates due to adverse events were 8 of 205 participants (3.9%) for brexpiprazole + sertraline and 20 of 196 participants (10.2%) for sertraline + placebo. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial show that brexpiprazole + sertraline combination treatment statistically significantly improved PTSD symptoms vs sertraline + placebo, indicating its potential as a new efficacious treatment for PTSD. Brexpiprazole + sertraline was tolerated by most participants, with a safety profile consistent with that of brexpiprazole in approved indications. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04124614.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Davis LL, Behl S, Lee D, et al. Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder: A Phase 3 Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 39693081. doi:10.1001/jamapsychiatry.2024.3996

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。